Nuwellis receives U.S. patent for dual lumen catheter design
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Nuwellis Awarded U.S. Patent for Novel Catheter Technology Designed to Enhance Extracorporeal Therapies
July 16, 2026 8:30 AM EDTMINNEAPOLIS, July 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,678,592, covering the companys Dual Lumen Catheter, a novel peripheral dual-lumen catheter designed for use with extracorporeal therapies, including ultrafiltration, dialysis, and continuous renal replacement therapy (CRRT) modalities. The patent was issued on July 14, 2026. It further expands Nuwellis' intellectual property portfolio and supports the Company's broader strategy of advancing differentiated technologies across the heart-kidney continuum. Nuwellis... More
